LEVERAGER Trademark

Trademark Overview

On Friday, May 27, 2022, a trademark application was filed for LEVERAGER with the United States Patent and Trademark Office. The USPTO has given the LEVERAGER trademark a serial number of 97432416. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Tuesday, October 15, 2024. This trademark is owned by Fosun Pharma USA Inc.. The LEVERAGER trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Drug discovery services; Research and development in the field of design of RNA-targeted drugs
leverager

General Information

Serial Number97432416
Word MarkLEVERAGER
Filing DateFriday, May 27, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateTuesday, October 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 21, 2023

Trademark Statements

Goods and ServicesDrug discovery services; Research and development in the field of design of RNA-targeted drugs

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, June 3, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameFosun Pharma USA Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08540
Party NameFosun Pharma USA Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08540

Trademark Events

Event DateEvent Description
Monday, December 5, 2022ASSIGNED TO EXAMINER
Tuesday, May 31, 2022NEW APPLICATION ENTERED
Friday, June 3, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 5, 2022NON-FINAL ACTION WRITTEN
Monday, December 5, 2022NON-FINAL ACTION E-MAILED
Monday, December 5, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, December 23, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, December 23, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, December 24, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 17, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 1, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 21, 2023PUBLISHED FOR OPPOSITION
Tuesday, February 21, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Friday, October 13, 2023SOU TEAS EXTENSION RECEIVED
Friday, October 13, 2023SOU EXTENSION 1 FILED
Tuesday, April 18, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, October 13, 2023SOU EXTENSION 1 GRANTED
Tuesday, October 15, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, October 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 15, 2024SOU EXTENSION 3 GRANTED
Tuesday, October 15, 2024SOU EXTENSION 3 FILED
Wednesday, February 7, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 5, 2024SOU TEAS EXTENSION RECEIVED
Monday, February 5, 2024SOU EXTENSION 2 FILED
Monday, February 5, 2024SOU EXTENSION 2 GRANTED

Related Keywords

leverager design targeted drugs field development discovery services research drug